Telix Showcases Innovation at ANZSNM 2025 Scientific Meeting

MELBOURNE, Australia, May 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces a strong presence at the 55th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2025), to be held in Melbourne, Australia from 23–25 May 2025.

Telix will feature prominently in the scientific program with eight oral and three poster presentations highlighting the Company's late-stage and next-generation programs. Demonstrating its commitment to development and education in theranostics, Telix presentations include:

• ProstACT Global Phase 3 study of TLX591 (¹⁷⁷Lu-rosopatamab tetraxetan)^[1], Telix's first-in-class PSMA^[2] targeting radio antibody-drug conjugate (rADC) therapy candidate
• STARSTRUCK study of TLX250 (¹⁷⁷Lu-girentuximab) in combination with peposertib^[3] in patients with carbonic anhydrase IX (CAIX)-expressing solid tumors^[4], and a preclinical evaluation of ²²⁵Ac-girentuximab in combination with DNA damage response inhibition
• Zolar study of TLX300-CDx (⁸⁹Zr-olaratumab)^[5], a theranostic approach in soft tissue sarcoma
• ZIRCON-CP study of TLX250-CDx (Zircaix®^[6], ⁸⁹Zr-girentuximab), Telix's kidney cancer PET^[7] radiodiagnostic candidate in Chinese patients with indeterminate renal masses^[8]
• TLX250-CDx early access in Australia and Italy highlighting clinical utility in clear cell renal cell carcinoma (ccRCC)
• D2, a first-in-class, dual-chelator theranostic that could enable the use of imaging-therapy radiometal pairs of different elements^[9]
• Artificial intelligence (AI) enabled PSMA-PET/CT^[10] lesion delineation for prostate cancer.

Telix will also host a Breakfast Symposium showcasing real-world experience and impact on clinical decision making with TLX250-CDx, and clinical utility of PSMA-PET. Again we are pleased to support the Nurses' Workshop in collaboration with with the Prostate Cancer Foundation of Australia (PCFA), NeuroEndocrine Cancer Australia (NECA) and the Peter MacCallum Cancer Centre in Melbourne.

Telix will be at booth #28, where visitors can learn more about Telix's extensive late-stage theranostic pipeline in urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and hematology, our associated medical technologies and AI innovations, and opportunities for collaboration.

Details of ANZSNM ASM 2025 abstract presentations related to Telix programs are listed below and the full congress program can be accessed here.

All times AEST.

Saturday, 24 May 2025

Title: Preclinical evaluation of DNA damage response inhibitors and ²²⁵Ac-DOTA-girentuximab combination therapy
Presenter: Zhipeng Cao, Olivia Newton-John Cancer Research Institute
Time: 11:00 AM – 12:30 PM
Session: RPS Session including Shimadzu Award
Location: Meeting Room 204

Title: D2 – Enabling a theranostic approach with ⁸⁹Zr/¹⁷⁷Lu in a single trifunctional ligand scaffold
Presenter: James Wood, The University of Queensland
Time: 11:00 AM – 12:30 PM
Location: Meeting Room 204
Session: RPS Session including Shimadzu Award

Sunday, 25 May 2025

Title: A preliminary study on nnUNet-based PSMA-PET/CT lesion segmentation models: toward clinically informed training
Presenter: David Han, Telix Pharmaceuticals
Time: 11:00 AM – 12:30 PM
Location: Meeting Room 204
Session: Scientific Session: Oncology 3

Title: ZOLAR, an open-label, Phase 1 study to assess safety, tolerability, dosimetry, pharmacokinetics, and imaging properties of ⁸⁹Zr-olaratumab (TLX300-CDx) in patients with soft tissue sarcoma
Presenter: Corinne Letendre, Telix Pharmaceuticals
Time: 11:00 AM – 12:30 PM
Location: Meeting Room 203
Session: Scientific Session: Therapy / Phase 1 Trials

Title: ProstACT Global, a multinational, multicenter, prospective, randomized, controlled, open-label, Phase 3 study of ¹⁷⁷Lu -rosopatamab tetraxetan (TLX591) in combination with standard of care (SoC) versus SoC alone in patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC) after androgen receptor pathway inhibitor (ARPI) treatment
Presenter: Veronica Wong, Nepean Hospital
Time: 11:00 AM – 12:30 PM
Location: Meeting Room 203
Session: Scientific Session: Therapy / Phase 1 Trials

Title: STARSTRUCK, a Phase 1b dose escalation/expansion study of the combination of ¹⁷⁷Lu-girentuximab (TLX250) and peposertib in patients with carbonic anhydrase IX (CAIX)-expressing solid tumors
Presenter: Aviral Singh, GenesisCare
Time: 11:00 AM – 12:30 PM
Location: Meeting Room 203
Session: Scientific Session: Therapy / Phase 1 Trials

Title: ZIRCON-CP, a confirmatory, open-label, single-arm, multicenter study to evaluate the safety, tolerability, and diagnostic performance of ⁸⁹Zr-girentuximab (TLX250-CDx) to non-invasively detect ccRCC by PET/CT imaging in Chinese patients with indeterminate renal masses
Presenter: Mary Jessel, Telix Pharmaceuticals
Time: 2:00 PM - 3:30 PM
Location: Meeting Room 207
Session: Scientific Session: Oncology Preclinical

Title: Preliminary investigation of radiation exposure of pathology staff from urine samples containing traces of ¹⁷⁷Lu-rosopatamab tetraxetan (TLX591)
Presenter: Alessandra Malaroda, Nepean Hospital
Time: 2:00 PM - 3:30 PM
Location: Meeting Room 204
Session: Scientific Session: Oncology 4

Posters: Displayed throughout meeting

Title: Non-invasive detection of Nectin-4 and TROP2 in bladder cancer via ImmunoPET
Presenter: Peter Chandler, Telix Pharmaceuticals

Title: Initial experience with ⁸⁹Zr-girentuximab (TLX250-CDx)
Presenter: Alexis Dalagiorgos, Jones Radiology

Title: The emerging role of ⁸⁹Zr-girentuximab (TLX250-CDx) PET/CT in the management of ccRCC: Early experience in three patients
Presenter: Fabrizia Gelardi, Università Vita-Salute San Raffaele, Milan (Italy)

Breakfast Session and Nurses Workshop

Telix-Hosted Breakfast
Location: Meeting Room 203
Date and Time: Sunday, 25 May | 7:15 AM – 8:15 AM
Topics and Presenters:

• Enhancing cancer care with precision radiopharmaceuticals: Expanded access for renal cancers – Sze Ting Lee, Austin Health
• Early diagnosis with PSMA-PET in prostate cancer – Michael Kitchener, Jones Radiology

Nurses Workshop
Location: Meeting Room 205
Date and Time: Saturday, 24 May | 12:30 PM – 1:30 PM
Topics and Presenters:

• Interpreting liver function tests – Emma Boehm, Peter MacCallum Cancer Centre
• Gallium-68 PET, FDG PET and other imaging modalities – Aaron Wong, Peter MacCallum Cancer Centre
• Managing toxicities in theranostics – Gabby Cehic AM, SA Health
• Radiation safety during radiopharmaceutical therapy – Daniel Badger, SA Health